Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Mineralys Therapeutics, Inc. MLYS NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$46.00
+68.4%

Mineralys Therapeutics, Inc. (MLYS) is a Biotechnology company in the Healthcare sector, currently trading at $27.32. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is MLYS = $46 (+68.4% upside).

Valuation: MLYS trades at a trailing Price-to-Earnings (P/E) of -14.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.96.

Net income is $155M (loss), growing at -91.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $647M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 43.76 (strong liquidity). Debt-to-assets is 0%. Total assets: $662M.

Analyst outlook: 7 / 8 analysts rate MLYS as buy (88%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$46.00
▲ 68.37% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Mineralys Therapeutics, Inc., the average price target is $46.00, with a high forecast of $56.00, and a low forecast of $30.00.
Highest Price Target
$56.00
Average Price Target
$46.00
Lowest Price Target
$30.00

MLYS SharesGrow Score Overview

69/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 94/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MLYS

✓
VALUE Pass
94/100
MLYS trades at a trailing Price-to-Earnings (P/E) of -14.3 (S&P 500 average ~25). Forward PEG 0.96 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $46, implying +68.4% from the current price $27. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
MLYS: +0%/yr revenue is, -91.9%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet MLYS: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 43.76 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
MLYS: Gross margin is 0% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 7 / 8 analysts rate MLYS as buy (88%). Analyst consensus target is $46 (+68.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range10.44-47.65
Volume524.61K
Avg Volume (30D)1.22M
Market Cap$1.81B
Beta (1Y)0.69
Share Statistics
EPS (TTM)-2.29
Shares Outstanding$67.66M
IPO Date2023-02-10
Employees51
CEOJon Congleton
Financial Highlights & Ratios
Gross Profit$-59K
EBITDA$-170.6M
Net Income$-154.65M
Operating Income$-170.6M
Total Cash$656.64M
Net Debt$-172.92M
Total Assets$661.81M
Price / Earnings (P/E)-11.9
Analyst Forecast
1Y Price Target$52.00
Target High$56.00
Target Low$30.00
Upside+90.3%
Rating ConsensusBuy
Analysts Covering8
Buy 88% Hold 13% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS6031701013

Price Chart

Track all markets on TradingView
MLYS
Mineralys Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
10.44 52WK RANGE 47.65

People Also View

SRRK
SRRK
Scholar Rock Holding Corporation
$49.53
+0.02%
 CDTX
CDTX
Cidara Therapeutics, Inc.
$221.38
+0.00%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 CPRX
CPRX
Catalyst Pharmaceuticals, Inc.
$26.19
+3.35%
 BEAM
BEAM
Beam Therapeutics Inc.
$30.30
+0.40%
 IDYA
IDYA
IDEAYA Biosciences, Inc.
$32.35
-1.43%
 ZLAB
ZLAB
Zai Lab Limited
$21.96
+2.91%
 ADPT
ADPT
Adaptive Biotechnologies Corporation
$14.53
+2.83%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message